Inhibiting the NLRP3 inflammasome with MCC950 ameliorates muscle atrophy in cancer cachexia
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2026.178654 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Xiaojuan Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Cachexia, Inflammasomes, Muscular Atrophy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Cancer cachexia-associated muscle atrophy represents a critical clinical challenge in advanced malignancies. Cancer cachexia is known as an inflammation-related disease, and the NoD-like receptor family pyrin domain-3 (NLRP3) inflammasome plays a significant role in cancer cachexia, especially in muscle atrophy. In the present study, the efficacy of MCC950, a selective NLRP3 inhibitor, on cancer cachexia-associated muscle atrophy was observed both in cultured C2C12 myotubes underwent various simulated cancer cachexia injuries and in cancer cachexia model mice bearing C26 colon tumor cells. In vitro, MCC950 alleviated C2C12 myotube atrophy induced by conditioned medium from tumor or tumor-macrophage co-cultures. In vivo, MCC950 markedly attenuated cachexia symptoms such as body weight loss and muscle atrophy in C26 tumor-bearing mice. Mechanistically, in tumor or tumor-macrophage co-culture, MCC950 suppresses NLRP3 inflammasome activation, reduces IL-1β and IL-18 release, subsequently decreases the potency of inducing NF-κB activation and Atrogin-1-mediated ubiquitin-proteasome degradation in myotubes, thereby attenuates C2C12 myotube atrophy. Furthermore, in muscle cells, MCC950 directly silences NLRP3 inflammasome signaling, inhibits pyroptosis and IL-1β/IL-18 secretion, suppresses muscle protein degradation to rescue cancer cachexia-driven muscle atrophy. These findings revealed the important role of NLRP3 inflammasome in cancer cachexia and also suggested the possibility of developing NLRP3 inflammasome inhibitors such as MCC950 to be novel therapeutic candidates for cancer cachexia treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.
- School of Pharmacy, East China Normal University, Shanghai, 200062, China.
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201003, China. Electronic address: xuanliu@shutcm.edu.cn.
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China. Electronic address: xwzhang@…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Pan, X., Fu, J., Gu, X., Fan, M., Pan, L., Zhao, Y., Liu, X., & Zhang, X. (2026). Inhibiting the NLRP3 inflammasome with MCC950 ameliorates muscle atrophy in cancer cachexia. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178654
Vancouver
Pan X, Fu J, Gu X, Fan M, Pan L, Zhao Y, et al. Inhibiting the NLRP3 inflammasome with MCC950 ameliorates muscle atrophy in cancer cachexia. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178654
BibTeX
@article{Pan2026,
author = {Pan, Xiaojuan and Fu, Junjie and Gu, Xiaofan and Fan, Meng and Pan, Lixuan and Zhao, Yun and Liu, Xuan and Zhang, Xiongwen},
title = {Inhibiting the NLRP3 inflammasome with MCC950 ameliorates muscle atrophy in cancer cachexia},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2026.178654}
}
EUVIMED